Recursion Pharmaceuticals, Inc.
NASDAQ:RXRXBiotechnology
+$0.04 today
- Market cap
- $1.76B
- Beta
- 1.00
- P/E (TTM)
- -3.0
- EPS (TTM)
- -$1.06
Volume 41.13M
Average 15.60M
RXRX EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Recursion Pharmaceuticals, Inc.NASDAQ: RXRX
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA remains negative
Q2 FY2026 EBITDA was -$112.53M, compared with -$147.57M a year earlier. Trailing-twelve-month EBITDA was -$444.45M.
Context
- EBITDA amounted to 749.0% of revenue in FY2025, up 23.8 pp from a year earlier.
- EBITDA grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 6 analysts of -$326.57M (+41.6%) for the fiscal year ending Dec 2026, a step up from the -31.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$112.53M-10.2% QoQ
- Last fiscal yearDec 2025
- -$559.38M-31.1% YoY
- LTMJun 2026
- -$444.45M+23.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +23.7% | +27.7% | +3.9 pp |
| 1 year | -31.1% | +41.6% | +72.7 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (559.38M) USD
- Year-over-year change
- -31.1%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (559.38M) | -31.1% |
| FY2024 | 2024-12-31 | (426.72M) | -38.7% |
| FY2023 | 2023-12-31 | (307.63M) | -35.1% |
| FY2022 | 2022-12-31 | (227.67M) | -30.0% |
| FY2021 | 2021-12-31 | (175.12M) | — |
EBITDA vs competitors
How RXRX compares with its peers on the latest reported figures
- RXRX's LTM Jun 2026 EBITDA of -$444.45M is the 3rd highest of the 4 companies compared; the peer median is -$283.83M.
- Its year-over-year change of +23.8% is the highest of 4, against a peer median of -6.5%.
- EBITDA amounts to 810.2% of revenue for RXRX, versus a peer median of 2742.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$119.51M | -312.9% | — | 597.6% | |
| LTM Jun 2026 | -$283.83M | +7.4% | — | 2742.3% | |
| LTM Jun 2026 | -$444.45M | +23.8% | — | 810.2% | |
| LTM Jun 2026 | -$498.21M | -6.5% | — | 13823.7% | |
| Peer median (excluding RXRX) | -$283.83M | -6.5% | — | 2742.3% | |
Competitors are the stored peer set for RXRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 10M | 39.68M | 43.88M | 58.84M | 74.68M |
| Cost of Revenue | 0 | 48.28M | 42.59M | 45.24M | 120.95M |
| Gross Profit | 10M | (8.59M) | 1.29M | 13.6M | (46.27M) |
| Gross Margin | 100.0% | -21.7% | 2.9% | 23.1% | -62.0% |
| Research & Development | 135.27M | 155.7M | 241.23M | 314.42M | 425.27M |
| Selling, General & Admin | 57.68M | 81.6M | 110.82M | 178.18M | 176.59M |
| Operating Expenses | 192.78M | 237.13M | 351.35M | 492.61M | 601.86M |
| Depreciation & Amortization | 8.41M | 11.76M | 24.4M | 36.49M | 83.7M |
| EBITDA | (175.12M) | (227.67M) | (307.63M) | (426.72M) | (559.38M) |
| EBITDA Margin | -1751.2% | -573.7% | -701.1% | -725.2% | -749.0% |
| Operating Income | (182.78M) | (245.73M) | (350.06M) | (479M) | (648.13M) |
| Operating Margin | -1827.8% | -619.3% | -797.8% | -814.1% | -867.9% |
| Interest Income | 73K | 6.25M | 19.12M | 15.76M | 22.79M |
| Interest Expense | 2.95M | 55K | 97K | 1.57M | 1.81M |
| Other Income / Expenses | (3.7M) | 6.25M | 17.93M | 14.22M | 3.24M |
| Income Before Tax | (186.48M) | (239.48M) | (332.13M) | (464.79M) | (644.9M) |
| Pre-Tax Margin | -1864.8% | -603.5% | -757.0% | -789.9% | -863.5% |
| Income Tax Expense | 0 | 0 | (4.06M) | (1.13M) | (136K) |
| Net Income | (186.48M) | (239.48M) | (328.07M) | (463.66M) | (644.76M) |
| Net Margin | -1864.8% | -603.5% | -747.7% | -788.0% | -863.4% |
| EPS (Basic) | (1.05) | (1.36) | (1.58) | (1.69) | (1.44) |
| EPS (Diluted) | (1.05) | (1.36) | (1.58) | (1.69) | (1.44) |
| Weighted Avg Shares | 170.27M | 175.54M | 207.85M | 274.21M | 447.45M |
| Weighted Avg Shares (Diluted) | 170.27M | 175.54M | 207.85M | 274.21M | 447.45M |
Recursion Pharmaceuticals, Inc.
NASDAQ:RXRX
Intrinsic Alpha fair value
Locked
Current Price
$2.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.